MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Anavex Life Sciences Corp

Fermé

SecteurSoins de santé

10.98 -0.72

Résumé

Variation du prix de l'action

24h

Actuel

Min

10.72

Max

11.2

Chiffres clés

By Trading Economics

Revenu

915K

-11M

Employés

42

EBITDA

106K

-12M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+157.69% upside

Dividendes

By Dow Jones

Prochains Résultats

5 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

201M

928M

Ouverture précédente

11.7

Clôture précédente

10.98

Sentiment de l'Actualité

By Acuity

50%

50%

154 / 376 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Anavex Life Sciences Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

18 juil. 2025, 21:01 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 20:50 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 20:46 UTC

Résultats

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18 juil. 2025, 20:39 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 20:36 UTC

Résultats

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18 juil. 2025, 20:16 UTC

Acquisitions, Fusions, Rachats

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18 juil. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 20:02 UTC

Market Talk

Gold Higher to Close Out Week -- Market Talk

18 juil. 2025, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18 juil. 2025, 19:06 UTC

Market Talk

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18 juil. 2025, 18:24 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18 juil. 2025, 18:19 UTC

Résultats

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18 juil. 2025, 18:11 UTC

Acquisitions, Fusions, Rachats

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18 juil. 2025, 18:11 UTC

Résultats

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18 juil. 2025, 17:35 UTC

Market Talk

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18 juil. 2025, 16:29 UTC

Market Talk

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18 juil. 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18 juil. 2025, 16:22 UTC

Résultats

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Tech, Media & Telecom Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Auto & Transport Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Energy & Utilities Roundup: Market Talk

18 juil. 2025, 16:20 UTC

Market Talk
Résultats

Basic Materials Roundup: Market Talk

18 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 juil. 2025, 16:04 UTC

Résultats

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18 juil. 2025, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

18 juil. 2025, 15:58 UTC

Market Talk

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18 juil. 2025, 15:47 UTC

Market Talk
Résultats

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Comparaison

Variation de prix

Anavex Life Sciences Corp prévision

Objectif de Prix

By TipRanks

157.69% hausse

Prévisions sur 12 Mois

Moyen 28.5 USD  157.69%

Haut 42 USD

Bas 15 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

8.275 / 9.312Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

154 / 376Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.